Company: PSTV
Filing Date: 2025-08-12
Form Type: S-1
Source: 0001193125-25-178940
Chunk: 6

Company: PLUS THERAPEUTICS, INC.
Filing Date: 2025-08-12
Form: S-1
Chunk 6
---
 test, which is a laboratory developed test, to be re-introduced to the U.S. market starting in the second half quarter of 2025 after we complete a number of
steps related to certifications, state licensure, payor coverages, reimbursement codes and financing.

Corporate Information

In March 2025, we moved our headquarters to Houston, Texas, in proximity to world-class cancer institutions and researchers. Our principal
executive offices are located at 2710 Reed Road, Suite 160, Houston, Texas 77051, and our telephone number is (737) 255-7194. We maintain a website at www.plustherapeutics.com. We make available free of charge
through our website our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q and Current Reports on Form 8-K, and
amendments to these reports filed or furnished pursuant to Section 13(a) or 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), as soon as reasonably practicable after we electronically file such material
with, or furnish such material to, the SEC. These reports and other information are also available, free of charge, at www.sec.gov. Information contained on, or that can be accessed through, the websites referenced in this prospectus are not a part
of, or incorporated by reference into, this prospectus.

1

THE OFFERING

| Shares of our common stock offered by the selling stockholder | Up to 33,000,000 shares of our common stock, subject to certain limitations described in this prospectus, consisting of (a) 31,387,097 shares of common stock which we may issue and sell to Lincoln Park from time to time, at our sole discretion, 
 during the 36-month period that began on the Commencement Date in accordance with the Purchase Agreement, and (b) 1,612,903 shares of common stock, which are the Initial Commitment Shares, for which we                                            
 received no cash consideration.                                                                                                                                                                                                                      |

| Shares of our common stock outstanding prior to this offering (as of August 8, 2025) | 99,264,526 shares of our common stock. |

| Shares of our common stock to be outstanding 
 after this offering                          | 132,264,526 shares of our common stock, assuming the sale of all the shares of common stock registered hereunder to Lincoln Park under the Purchase Agreement. The actual number of